CAR-T Cell Therapy and Bispecific Antibody Resustomino: Roche signs $2 billion partnership agreement with Cinda Bio

Swiss pharmaceutical giant Roche has reached an agreement with Innovention Biologics to develop a common CAR-T cell therapy and 2:1 T-cell bispecific antibodies for blood and solid cancersRoche's 2:1 T-cell bispecific antibodies (Image: Roche) Under the terms of the agreement, Sunda Bio, based in Suzhou, China, will pay upfront costs for the use of Roche's technology, as well as development, commercial milestone payments and royaltiesIf all products are successfully developed and commercialized, Roche will pay up to $140 million to Innovent, plus an additional $1.96 billion in development, approval and sales milestone paymentsRoche will also pay double-digit royalties for each product that it chooses to develop and commercialize"Innovent first entered the field of cell therapy a few years ago, in partnership with Roche, we will take a bolder step toward strengthening our cell therapy platform based on Roche's innovative universal CAR-T cell technology and continue to develop and commercialize new bimolecule-specificity using Roche's 2:1 T-cell bispecific antibody platform," said Innovent's Chairman and CEOIn 2015, Innovents signed an agreement with Lilly to jointly develop at least three experimental anti-cancer drugs, which led to the development and eventual approval of its cancer immunotherapy anti-PD-L1 anti-Tyvyt (sintilimab) in ChinaTyvyt was approved by the State Administration of Drug Administration of China in December 2018 for the treatment of recurrent and refractive classic Hodgkin lymphoma (cHL)